PMID- 24739285
OWN - NLM
STAT- MEDLINE
DCOM- 20140912
LR  - 20211021
IS  - 1743-422X (Electronic)
IS  - 1743-422X (Linking)
VI  - 11
DP  - 2014 Apr 16
TI  - Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 
      hemagglutinin and neuraminidase antibodies provides dose-dependent protection 
      against lethal virus challenge in SCID mice.
PG  - 70
LID - 10.1186/1743-422X-11-70 [doi]
AB  - BACKGROUND: Convalescent plasma and fractionated immunoglobulins have been 
      suggested as prophylactic or therapeutic interventions during an influenza 
      pandemic. FINDINGS: Intravenous immunoglobulin (IVIG) preparations manufactured 
      from human plasma collected before the 2009 H1N1 influenza pandemic, and 
      post-pandemic hyperimmune (H)-IVIG preparations were characterized with respect 
      to hemagglutination inhibition (HI), microneutralization (MN) and 
      neuraminidase-inhibiting (NAi) antibody titers against pandemic H1N1 (pH1N1) and 
      seasonal H1N1 (sH1N1) viruses. The protective efficacy of the IVIG and H-IVIG 
      preparations was evaluated in a SCID mouse challenge model.Substantial levels of 
      HI, MN and NAi antibodies against pH1N1 (GMTs 1:45, 1:204 and 1: 727, 
      respectively) and sH1N1 (GMTs 1:688, 1:4,946 and 1:312, respectively) were 
      present in pre-pandemic IVIG preparations. In post-pandemic H-IVIG preparations, 
      HI, MN and NAi antibody GMTs against pH1N1 were 1:1,280, 1:11,404 and 1:2,488 
      (28-, 56- and 3.4-fold enriched), respectively, compared to pre-pandemic IVIG 
      preparations (p < 0.001). Post-pandemic H-IVIG (HI titer 1:1,280) provided 
      complete protection from lethality of SCID mice against pH1N1 challenge (100% of 
      mice survived for 29 days post-challenge). Pre-pandemic IVIG (HI titer 1:70) did 
      not provide significant protection against pH1N1 challenge (50% of mice survived 
      29 days post-challenge compared to 40% survival in the buffer control group). 
      There was a highly significant correlation between circulating in vivo HI and MN 
      antibody titers and survival (p < 0001). CONCLUSION: The substantial enrichment 
      of HA- and NA-specific antibodies in H-IVIG and the efficacious protection of 
      SCID mice against challenge with pH1N1 suggests H-IVIG as a promising 
      intervention against pandemic influenza for immunocompromised patients and other 
      risk groups.
FAU - Hohenadl, Christine
AU  - Hohenadl C
FAU - Wodal, Walter
AU  - Wodal W
FAU - Kerschbaum, Astrid
AU  - Kerschbaum A
FAU - Fritz, Richard
AU  - Fritz R
FAU - Howard, M Keith
AU  - Howard MK
FAU - Farcet, Maria R
AU  - Farcet MR
FAU - Portsmouth, Daniel
AU  - Portsmouth D
FAU - McVey, John K
AU  - McVey JK
FAU - Baker, Donald A
AU  - Baker DA
FAU - Ehrlich, Hartmut J
AU  - Ehrlich HJ
FAU - Barrett, P Noel
AU  - Barrett PN
FAU - Kreil, Thomas R
AU  - Kreil TR
AD  - Global Pathogen Safety, Baxter BioScience, Benatzkygasse 2-6, 1221 Vienna, 
      Austria. thomas_kreil@baxter.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140416
PL  - England
TA  - Virol J
JT  - Virology journal
JID - 101231645
RN  - 0 (Antibodies, Viral)
RN  - 0 (Hemagglutinin Glycoproteins, Influenza Virus)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Viral Proteins)
RN  - EC 3.2.1.18 (NA protein, influenza A virus)
RN  - EC 3.2.1.18 (Neuraminidase)
SB  - IM
MH  - Animals
MH  - Antibodies, Viral/*administration & dosage
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Hemagglutinin Glycoproteins, Influenza Virus/*immunology
MH  - Immunocompromised Host
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Influenza A Virus, H1N1 Subtype/*immunology
MH  - Mice
MH  - Mice, SCID
MH  - Neuraminidase/*antagonists & inhibitors/immunology
MH  - Orthomyxoviridae Infections/*prevention & control
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Viral Proteins/*antagonists & inhibitors/immunology
PMC - PMC3996311
EDAT- 2014/04/18 06:00
MHDA- 2014/09/13 06:00
PMCR- 2014/04/16
CRDT- 2014/04/18 06:00
PHST- 2014/01/24 00:00 [received]
PHST- 2014/04/07 00:00 [accepted]
PHST- 2014/04/18 06:00 [entrez]
PHST- 2014/04/18 06:00 [pubmed]
PHST- 2014/09/13 06:00 [medline]
PHST- 2014/04/16 00:00 [pmc-release]
AID - 1743-422X-11-70 [pii]
AID - 10.1186/1743-422X-11-70 [doi]
PST - epublish
SO  - Virol J. 2014 Apr 16;11:70. doi: 10.1186/1743-422X-11-70.